APPILI THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.035 CAD | -12.50% |
|
-12.50% | -.--% |
| Apr. 26 | Appili Therapeutics Inc. announced that it has received CAD 0.3 million in funding | CI |
| Apr. 02 | Appili Therapeutics To be Acquired by Aditxt, Inc. | MT |
Valuation
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 31.55 | 69.68 | 8.552 | 4.851 | 4.244 | - | - |
| Enterprise Value (EV) 1 | 31.55 | 69.68 | 8.552 | 4.851 | 4.244 | 4.244 | 4.244 |
| P/E ratio | -4.25 x | -4.63 x | -0.32 x | -0.5 x | -0.65 x | -0.65 x | -0.65 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 158 x | - | 6 x | 13.3 x | - | - | - |
| EV / Revenue | 158 x | - | 6 x | 13.3 x | - | - | - |
| EV / EBITDA | - | -5,331,969 x | -398,279 x | - | - | - | - |
| EV / FCF | -7,404,388 x | -6,080,848 x | - | - | - | - | - |
| FCF Yield | -0% | -0% | - | - | - | - | - |
| Price to Book | - | 5.47 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 46,401 | 62,776 | 71,266 | 121,266 | 121,266 | - | - |
| Reference price 2 | 0.6800 | 1.110 | 0.1200 | 0.0400 | 0.0350 | 0.0350 | 0.0350 |
| Announcement Date | 6/24/20 | 6/24/21 | 6/29/22 | 6/23/23 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.1991 | - | 1.424 | 0.3641 | - | - | - |
| EBITDA | - | - | -13.07 | -21.47 | - | - | - | - |
| EBIT 1 | - | -6.092 | -15.66 | -24.62 | -7.884 | -8.415 | -10.32 | -10.72 |
| Operating Margin | - | -3,059.51% | - | -1,728.55% | -2,165.69% | - | - | - |
| Earnings before Tax (EBT) 1 | - | -5.416 | -14.33 | -25.08 | -9.207 | -6.922 | -10.32 | -10.72 |
| Net income 1 | -4.331 | -5.416 | -14.3 | -25.12 | -9.2 | -6.922 | -10.32 | -10.72 |
| Net margin | - | -2,720.36% | - | -1,763.42% | -2,527.06% | - | - | - |
| EPS 2 | -0.1400 | -0.1600 | -0.2400 | -0.3800 | -0.0800 | -0.0540 | -0.0540 | -0.0540 |
| Free Cash Flow | - | -4.261 | -11.46 | - | - | - | - | - |
| FCF margin | - | -2,140.22% | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 7/3/19 | 6/24/20 | 6/24/21 | 6/29/22 | 6/23/23 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.00494 | 1.391 | 0.00547 | 0.00484 | 0.00909 | - | 0.3408 | 0.00833 | 0.3397 | 0.484 | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -11.17 | -3.299 | -2.444 | -2.059 | -1.186 | -2.423 | -2.225 | -2.223 | -1.48 | -1.914 | -2.172 |
| Operating Margin | -226,176.11% | -237.21% | -44,678.24% | -42,540.91% | -13,046.09% | - | -653.02% | -26,683.55% | -435.87% | -395.48% | - |
| Earnings before Tax (EBT) 1 | -11.17 | -3.23 | -3.334 | -2.314 | -1.653 | -2.585 | -2.654 | -1.536 | -0.9345 | -0.1462 | -2.172 |
| Net income 1 | -11.18 | -3.239 | -3.333 | -2.325 | -1.638 | -2.619 | -2.647 | -1.5 | -0.9766 | -0.1523 | -2.172 |
| Net margin | -226,248.18% | -232.91% | -60,940.59% | -48,032.23% | -18,022.22% | - | -776.77% | -18,007.2% | -287.51% | -31.48% | - |
| EPS 2 | -0.1800 | -0.0500 | -0.0500 | - | -0.0100 | -0.0200 | -0.0200 | - | - | - | -0.0140 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/12/21 | 2/14/22 | 6/29/22 | 8/12/22 | 11/10/22 | 2/14/23 | 6/23/23 | 8/11/23 | 11/14/23 | 2/13/24 | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | -4.26 | -11.5 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | -133% | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | 0.2000 | - | - | - | - | - |
| Cash Flow per Share | - | - | -0.1900 | - | - | - | - | - |
| Capex | - | 0 | 0.01 | - | - | - | - | - |
| Capex / Sales | - | 0.54% | - | - | - | - | - | - |
| Announcement Date | 7/3/19 | 6/24/20 | 6/24/21 | 6/29/22 | 6/23/23 | - | - | - |
1CAD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 3.09M | |
| -3.46% | 102B | |
| +1.41% | 96.09B | |
| +2.13% | 22.28B | |
| -15.84% | 21.4B | |
| -9.98% | 18.14B | |
| -39.98% | 17.02B | |
| -14.65% | 16.09B | |
| +4.39% | 13.83B | |
| +31.35% | 11.97B |
- Stock Market
- Equities
- APLI Stock
- Financials Appili Therapeutics Inc.
